Hebrew University professor in Jerusalem is an expert on obesity and metabolic syndrome
TEL AVIV, VANCOUVER, ISRAEL/CANADA, May 8, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “Company”), A biotechnology company focused on the discovery and development of new psychedelic-derived therapeutics to solve major undertreated health problems, brings Professor Joseph (Yossi) Tam, DMD, Ph.D. Appointed to the Scientific Advisory Board (“SAB”). Professor Tam is Director of the Obesity and Metabolism Institute and Director of the Interdisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem.
Professor Tam is also a member of the Harvey M. Kruger Family Center for Nanoscience and Nanotechnology, president of the International Association for Cannabinoid Research, and postdoctoral fellow at NIH’s National Institute on Alcohol Abuse and Alcoholism (NIAAA). there was. .
Clearmind CEO Dr. Adi Zuloff-Shani said: “We are very encouraged by the preclinical data from Prof. Tam’s lab because we believe it will make a big difference for patients suffering from obesity and metabolic disorders, who currently have limited options available. is.”
“Our strong IP portfolio includes a number of innovative compounds in the field of psychedelic-derived therapeutics, and preclinical data show that they make a significant difference in obese patients, improving weight loss and insulin levels. It suggests that it may contribute to normalization,” added Dr. Zuloff-Shani. .
Professor Tam said: “By joining Clearmind Medicine’s Scientific Advisory Board, we look forward to making significant progress in the discovery and development of new treatments for psychedelic-derived obesity and metabolic disorders.”
About Clearmind Medicine
Clearmind is a psychedelic pharmaceutical biotechnology company focused on the discovery and development of new psychedelic-derived therapeutics to solve a wide range of underserved health problems, including alcohol use disorders. I guess. Its primary purpose is to research and develop psychedelic-based compounds and commercialize them as regulated drugs, foods, or supplements.
The company’s intellectual portfolio currently consists of 14 patent families. The company intends to seek additional patents for its compounds whenever warranted, and remains opportunistic in acquiring additional intellectual property to build its portfolio.
Clearmind shares are traded on the Nasdaq and Canadian Stock Exchanges under the symbol “CMND” and on the Frankfurt Stock Exchange under the symbol “CWY”.
See below for more information. https://www.clearmindmedicine.com or contact:
PR for investors
Investment@clearmindmedicine.com
Phone: (604) 260-1566
General inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expect”, “expect”, “intend”, “plan”, “believe”, “seek”, “estimate” and similar expressions or variations of such words are It is intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations, beliefs and projections rather than historical facts, many of which are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from those expressed or indicated in the forward-looking statements. Furthermore, we cannot guarantee that any patents will issue as a result of pending patent applications or, if they do, that they will issue in our favor. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For more information on the risks and uncertainties that affect us, please refer to our reports filed from time to time with the U.S. Securities and Exchange Commission (“SEC”). Our Annual Report on Form 20-F filed with the SEC on February 6, 2023. To reflect changes in actual results, subsequent events or circumstances, changes in assumptions or other factors affecting forward-looking information, except to the extent required by applicable securities laws. does not undertake any obligation to update any forward-looking statements. Even if we update one or more forward-looking statements, no inference should be taken that we will make additional updates with respect to it or any other forward-looking statement. References and links to websites are provided as a convenience, and information contained in such websites is not incorporated by reference into this press release. Clearmind is not responsible for the content of third party websites.
